相关实验视频

Updated: Jul 26, 2025

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy

Measurement of Liver Stiffness Using Atomic Force Microscopy Coupled with Polarization Microscopy

Published on: July 20, 2022

慢性乙型肝炎患者使用过渡性弹性学评估的肝硬度值的变化:一个前性观察性研究

Heejin Cho¹, Yun Bin Lee^2,3, Yeonjung Ha⁴

¹Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.

BMC gastroenterology

|June 15, 2023

概括

在慢性乙肝 (CHB) 患者中,长期的特诺福维尔双醇烟酸 (TDF) 治疗显著降低了肝硬度 (LS). 这项研究显示,LS在144周内显著下降,表明潜在的纤维化回归.

科学领域:

肝病学肝病学是一种肝病学.
病毒学病毒学
纤维化研究纤维化.

背景情况:

在慢性乙型肝炎 (CHB) 抗病毒治疗期间,已知肝纤维化的回归.
有限的数据存在于长期的特诺福维尔二氧化 fumarate (TDF) 对肝硬度 (LS) 在CHB患者的影响.
过渡性弹性图是评估肝硬度的一个关键工具.

研究的目的:

为了研究144周TDF治疗期间肝硬度 (LS) 的变化.
评估TDF对以前未接受治疗的CHB患者肝纤维化标志物的影响.
为了确定在TDF治疗期间LS减少的预测因素.

主要方法:

从2015年4月到2020年7月进行的前性观察研究.
在基线和12周,24周,48周,96周和144周进行的LS测量和实验室测试.
定义显著的LS下降为96.6周与基线相比≥30%的下降.

主要成果:

平均LS值从基线时的13.8 kPa显著下降到第144周的6.4 kPa (P < 0.001).
58.3%的患者在96.6周前出现显著的LS下降.
较高的基线LS是96周LS减少的唯一独立预测因子.

结论:

144周的TDF治疗导致以前未接受治疗的CHB患者的肝硬度显著下降.
TDF在减少肝硬度方面表现出有效性,这表明潜在的纤维化回归.
长期的TDF治疗是有效的管理肝纤维化在CHB.

关键词:

慢性乙型肝炎慢性乙型肝炎肝脏硬肝脏硬肝脏硬诺福维尔二氧化二氧化 fumarate 的使用情况短暂的弹性图形 (elastography) 是一种短暂的弹性图形.

更多相关视频

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH

Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH

Published on: April 20, 2021

相关概念视频

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...

Diseases of the Liver and Gallbladder

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...

Hepatic Drug Excretion: Influencing Factors

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...